Author's response to reviews

Title: A phase-II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

Authors:

Kazuhisa Yamaguchi (kazuhisa.yamaguchi@med.toho-u.ac.jp)
Hiroya Taniguchi (h.taniguchi@aichi-cc.jp)
Azusa Komori (a.komori@aichi-cc.jp)
Yukiya Narita (yukiya.narita@aichi-cc.jp)
Sohei Nitta (shntt2@gmail.com)
Motoo Nomura (mnomura@kuhp.kyoto-u.ac.jp)
Shigenori Kadowaki (skadowaki@aichi-cc.jp)
Daisuke Takahari (daisuke.takahari@jfc.or.jp)
Takashi Ura (tura@aichi-cc.jp)
Masashi Andoh (mandoh@aichi-cc.jp)
Kei Muro (kmuro@aichi-cc.jp)
Keita Mori (ke.mori@scchr.jp)
Yoshinori Igarashi (igarashi@med.toho-u.ac.jp)

Version: 6 Date: 13 August 2015

Author's response to reviews: see over
Dear Dr. Manoj Pandey

Re: “A phase-II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer” by Kazuhisa Yamaguchi, Hiroya Taniguchi, Azusa Komori, Yukiya Narita, Sohei Nitta, Motoo Nomura, Shigenori Kadowaki, Daisuke Takahari, Takashi Ura, Masashi Andoh, Kei Muro, Keita Mori and Yoshinori Igarashi; MS. No 1755515626154829.

Please find attached, the revised version of our paper. We are most grateful to you and the referee for the helpful comments on the original version of our manuscript. We have taken the comment into account.

We have addressed all the comments by reviewer Dr. Andrea Evangelista, as indicated on the attached pages, and we hope that our explanation and revisions are satisfactory.

We hope that the revised version of our paper is now suitable for publication in the *BMC cancer* and we look forward to hearing from you at your earliest convenience.

Sincerely,

Corresponding author: Hiroya Taniguchi

Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan
Email Address: h.taniguchi@aichi-cc.jp
We are grateful to reviewer Dr. Andrea Evangelista for the special comments and useful suggestions for editorial revisions. We revised as follows.

**Editorial Requests:**
1) Please include the trial registration date at the end of the Abstract
2) Please include details of each author's contribution in the Authors contributions section. At the moment, only three authors are listed.
3) Please include details of funding in the Acknowledgements section

**Answers**
Thank you for your suggestions. I modified and included the registration date (page 4, line 5-7), details of each author's contribution (page 18, line 9-12) and details of funding (page 18, line 15-17).